BONESUPPORT Enrolls First Patient in FORTIFY Trial With CERAMENT G

BONESUPPORT enrolled the first patient in the pivotal Investigational Device Exemption FORTIFY trial, "A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures."

The trial will enroll up to 230 patients at up to 30 centers in the U.S. and Europe. BONESUPPORT received...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us